{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:48:48Z","timestamp":1789926528645,"version":"4.0.1"},"reference-count":339,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Melanoma is an aggressive neoplasia issued from the malignant transformation of melanocytes, the pigment-generating cells of the skin. It is responsible for about 75% of deaths due to skin cancers. Melanoma is a phenotypically and molecularly heterogeneous disease: cutaneous, uveal, acral, and mucosal melanomas have different clinical courses, are associated with different mutational profiles, and possess distinct risk factors. The discovery of the molecular abnormalities underlying melanomas has led to the promising improvement of therapy, and further progress is expected in the near future. The study of melanoma precursor lesions has led to the suggestion that the pathway of tumor evolution implies the progression from benign naevi, to dysplastic naevi, to melanoma in situ and then to invasive and metastatic melanoma. The gene alterations characterizing melanomas tend to accumulate in these precursor lesions in a sequential order. Studies carried out in recent years have, in part, elucidated the great tumorigenic potential of melanoma tumor cells. These findings have led to speculation that the cancer stem cell model cannot be applied to melanoma because, in this malignancy, tumor cells possess an intrinsic plasticity, conferring the capacity to initiate and maintain the neoplastic process to phenotypically different tumor cells.<\/jats:p>","DOI":"10.3390\/medsci5040028","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T11:35:45Z","timestamp":1511177745000},"page":"28","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells"],"prefix":"10.3390","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8942","authenticated-orcid":false,"given":"Ugo","family":"Testa","sequence":"first","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Pelosi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature11624","article-title":"An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair\/fair skin background","volume":"491","author":"Mitra","year":"2012","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ncomms1893","article-title":"Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment","volume":"3","author":"Noonan","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1755-148X.2011.00834.x","article-title":"Generation of melanocytes from neural crest cells","volume":"24","author":"Sommer","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.stem.2009.12.010","article-title":"Key roles for transforming growth factor \u03b2 in melanocyte stem cell maintenance","volume":"6","author":"Nishimura","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1242\/dev.073064","article-title":"Temporal control of neural crest lineage generation by Wnt\/\u03b2-catenin signaling","volume":"139","author":"Hari","year":"2012","journal-title":"Development"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2011.05.004","article-title":"Coordinated activation of Wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration","volume":"145","author":"Rabbani","year":"2011","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1101\/gad.298703.117","article-title":"Identification of hair shaft progenitors that create a niche for hair pigmentation","volume":"31","author":"Liao","year":"2017","journal-title":"Genes Dev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12709","DOI":"10.1073\/pnas.1306287110","article-title":"Neural crest and Schwann cell progenitor-derived melanocytes are two spatially segregated populations similarly regulated by Foxd3","volume":"110","author":"Nitzan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0046-8177(84)80310-X","article-title":"A study of tumor progression: The precursor lesions of superficial spreading and nodular melanomas","volume":"15","author":"Clark","year":"1984","journal-title":"Hum. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Muller","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_11","first-page":"89","article-title":"Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune","volume":"1826","author":"Niessen","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Vidwans, S.J., Flaherty, K.T., Fisher, D.E., Tenenbaum, J.M., Travers, M.D., and Shrager, J. (2011). A melanoma molecular disease model. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018257"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidom","year":"2010","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ccr.2011.10.030","article-title":"\u03b2-catenin signaling controls metastasis in BRAF-activated PTEN-deficient melanomas","volume":"20","author":"Damsky","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamadermatol.2014.436","article-title":"BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib","volume":"150","author":"Lin","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1479-5876-11-202","article-title":"Heterogeneous distribution of BRAF\/NRAS mutations among Italian patients with advanced melanoma","volume":"11","author":"Colombino","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jnci\/djp309","article-title":"Polyclonality of BRAF mutations in acquired melanocytic nevi","volume":"101","author":"Liu","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6606072","article-title":"Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression","volume":"104","author":"Liu","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients: Clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient homogeneity of BRAFV600E expression in melanoma","volume":"38","author":"Menzies","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nm.4155","article-title":"Loss of cohesion compolex components STAG2 or STAG3 confers resistance to BRAF inhibitioin in melanoma","volume":"22","author":"Shen","year":"2016","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/djs373","article-title":"Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma","volume":"104","author":"Jalili","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","article-title":"MAP Kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RFA\/MEK inhibition","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Wagel","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"77163","DOI":"10.18632\/oncotarget.12848","article-title":"Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance","volume":"7","author":"Raaijmakers","year":"2016","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.15252\/msb.20166796","article-title":"Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state","volume":"13","author":"Becker","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nm.4369","article-title":"An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer","volume":"23","author":"Xue","year":"2017","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","article-title":"PAK signaling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","volume":"550","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/exd.13002","article-title":"Therapeutic implications of melanoma heterogeneity","volume":"25","author":"Hachey","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12967-015-0401-8","article-title":"Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas","volume":"13","author":"Manca","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","article-title":"Melanoma genome sequencing reveals frequent PREX2 mutations","volume":"418","author":"Berger","year":"2012","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.1026","article-title":"Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma","volume":"44","author":"Nikolaev","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng.1041","article-title":"Frequent somatic mutations in MAP3K5 and PAP3K9 in metastatic melanoma identified by exome sequencing","volume":"44","author":"Stark","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ng.810","article-title":"Exome sequencing identifies GRIN2A as frequently mutated in melanoma","volume":"43","author":"Wei","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature09806","article-title":"The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset","volume":"471","author":"Ceol","year":"2011","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/ng.958","article-title":"Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3","volume":"43","author":"Macgregor","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/DAD.0b013e3182964e02","article-title":"Immunohistochemistry for histone H3 lysine 9 methyltransferase and demethylase proteins in human melanomas","volume":"36","author":"Miura","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.438","article-title":"Analysis of the tyrosine kinase in melanoma reveals recurrent mutations in ERBB4","volume":"41","author":"Prickett","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.18632\/oncotarget.2747","article-title":"Whole genome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma","volume":"6","author":"Wong","year":"2014","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature08658","article-title":"A comprehensive catalogue of somatic mutations from a human cancer genome","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Aydin, I.T., Melamed, R.D., Adams, S.J., Castillo-Martin, M., Demir, A., Bryk, D., Brunner, G., Cordon-Cardo, C., Osman, I., and Rabadan, R. (2014). FBXW7 mutations in melanoma and a new therapeutic paradigm. J. Natl. Cancer. Inst., 106.","DOI":"10.1093\/jnci\/dju107"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cao, J., Ge, M.H., and Ling, Z.Q. (2016). Fbxw7 tumor suppressor: A vital regulator contributes to human tumorigenesis. Medicine, 95.","DOI":"10.1097\/MD.0000000000002496"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/ncb3121","article-title":"FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification","volume":"17","author":"Kourtis","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/pcmr.12603","article-title":"FBXW7 inactivation in a BrafV600E-driven mouse model leads to melanoma development","volume":"30","author":"Aydin","year":"2017","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lovly, C.M., Dahlman, K.B., Fohn, L.E., Su, Z., Dias-Santagata, D., Hicks, D.J., Hucks, D., Berry, E., Terry, C., and Duke, M. (2012). Routine multiplex mutational profiling enables enrollment in genotype-driven therapeutic trials. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035309"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","article-title":"BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors","volume":"2","author":"Dahlman","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","article-title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition","volume":"19","author":"Utchinson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1158\/1535-7163.MCT-13-0804","article-title":"A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: A road map for the study of genes with potential clinical relevance","volume":"13","author":"Xia","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","article-title":"BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage","volume":"19","author":"Mar","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/nm.2941","article-title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma","volume":"18","author":"Kwong","year":"2012","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1200\/JCO.2005.07.168","article-title":"Prognostic significance of activated Akt expression in melanoma: A clinopathologic study of 292 cases","volume":"23","author":"Dai","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1101\/gad.187252.112","article-title":"Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis","volume":"26","author":"Vredeveld","year":"2012","journal-title":"Genes. Dev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cell.2011.09.032","article-title":"In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma","volume":"147","author":"Karreth","year":"2011","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1158\/0008-5472.CAN-13-3209","article-title":"NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK activation","volume":"75","author":"Namiki","year":"2015","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/CMR.0b013e32835e590e","article-title":"A large retrospective multicenter study of vaginal melanomas: Implications for new management","volume":"23","author":"Vayssa","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","article-title":"Large-scale analysis of KIT aberrations in chinese patients with melanoma","volume":"17","author":"Kong","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","article-title":"Sunitinib therapy for melanoma patients with kit mutations","volume":"18","author":"Minor","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/jid.2014.372","article-title":"KIT is a frequent target for epigenetic silencing in cutaneous melanoma","volume":"135","author":"Hansen","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/0008-5472.CAN-17-0473","article-title":"KIT suppresses BRAFV600E-mutant melanoma by attenuating oncogenic RAS\/MAPK signaling","volume":"77","author":"Neiswender","year":"2017","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/exd.12080","article-title":"Genetic regulation in Ras-regulated pathways in acral lentiginous melanoma","volume":"22","author":"Badens","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1101\/gr.213348.116","article-title":"Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma","volume":"27","author":"Liang","year":"2017","journal-title":"Gen. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13673","DOI":"10.1021\/jacs.6b07598","article-title":"A pharmacological chaperone molecule induces cancer cell death by restoring tertiary DNA structures in mutant hTERT promoters","volume":"138","author":"Kang","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00432-016-2322-1","article-title":"Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients","volume":"143","author":"Ofner","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Griewank, K.G., Murali, R., Puig-Batille, J.A., Schilling, B., Livingstone, E., Potrony, M., Carrera, C., Schimming, T., M\u00f6ller, I., and Schwamborn, M. (2014). TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J. Natl. Cancer Inst., 106.","DOI":"10.1093\/jnci\/dju246"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Seynnaeve, B., Lee, S., Borah, S., Park, Y., Pappo, A., Kirkwood, J.M., and Bahrami, A. (2017). Genetic and epigenetic alterations of TERT are associated with inferior outcome in adolescent and young adult patients with melanoma. Sci. Rep., 7.","DOI":"10.1038\/srep45704"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.3101","article-title":"Genome-wide analysis of noncoding regulatory mutations in cancer","volume":"46","author":"Werhold","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"14402","DOI":"10.1073\/pnas.1611106113","article-title":"Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas","volume":"113","author":"Li","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cell.2012.07.033","article-title":"Loss of 5-Hydroxymethyl-cytosine is an epigenetic hallmark of melanoma","volume":"150","author":"Lian","year":"2012","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.immuni.2017.07.020","article-title":"The DNA methylcytosine dioxygenase Tet2 sustains immunosuppressive function of tumor-infiltrating myeloid cells to promote melanoma progression","volume":"47","author":"Pan","year":"2017","journal-title":"Immunity"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/nm.2863","article-title":"MDM4 is a key therapeutic target in cutaneous melanoma","volume":"18","author":"Gembarska","year":"2012","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1172\/JCI82534","article-title":"Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth","volume":"126","author":"Dewaele","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jnci\/djt003","article-title":"The role of miR-18b in MDM2-p53 pathway signaling and melanoma progressing","volume":"105","author":"Dar","year":"2013","journal-title":"J. Natl. Cancer. Inst."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/jmcb\/mjw045","article-title":"AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex","volume":"9","author":"Luo","year":"2017","journal-title":"J. Mol. Cell. Biol."},{"key":"ref_86","unstructured":"The Cancer Genome Atlas Network (2015). Genomic classification of cutaneous melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","article-title":"Elucidating distinct roles for NF1 in melanomagenesis","volume":"3","author":"Maertens","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/2159-8290.CD-12-0470","article-title":"A genome scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition","volume":"3","author":"Whittaker","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1878-0261.12050","article-title":"NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics","volume":"11","author":"Cirenajwis","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Kong, Y., Sheng, X., Wu, X., Yan, J., Ma, M., Yu, J., Si, L., Chi, Z., Cui, C., and Dai, J. (2017). Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4\/6 inhibitors in targeted therapy. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-17-0070"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/jid.2014.425","article-title":"The genomic landscape of childhood and adolescent melanoma","volume":"135","author":"Lu","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00000478-198901000-00005","article-title":"Deep penetrating nevus","volume":"13","author":"Seab","year":"1989","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41467-017-00758-3","article-title":"Combined activation of MAP kinase pathway and \u03b2-catenin signaling cause deep penetrating nevi","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Poollock","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aao0535","article-title":"Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism","volume":"357","author":"Chiba","year":"2017","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/pde.13184","article-title":"Evolution of Spitz nevi","volume":"34","author":"Emirogly","year":"2017","journal-title":"Pediatr. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Wiesner, T., He, J., Yelensky, R., Esteve-Puig, R., Botton, T., Yeh, I., Lipson, D., Otto, G., Brennan, K., and Murali, R. (2014). Kinase fusions are frequent in Spitz tumors and spitzoid melanomas. Nat. Commun., 5.","DOI":"10.1038\/ncomms4116"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/path.4775","article-title":"NTRK3 kinase fusions in Spitz tumours","volume":"240","author":"Yeh","year":"2016","journal-title":"J. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/PAS.0000000000000761","article-title":"A comparison of morphologic and molecular features of BRAF, ALK, and NTRK1 fusion spitzoid neoplasms","volume":"41","author":"Amin","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/modpathol.2016.237","article-title":"Spitz nevi and spitzoid melanomas: Exome sequencing and comparison with conventional melanocytic nevi and melanomas","volume":"30","author":"Lazova","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Yeh, I., Botton, T., Talevich, E., Shain, A.H., Sparatta, A.J., de la Fouchardiere, A., Mully, T.W., North, J.P., and Garrido, M.C. (2016). Activating MET kinase rearrangements in melanoma and Spitz tumors. Nat. Commun., 6.","DOI":"10.1038\/ncomms8174"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Lee, S., Barnhill, R.L., Dummer, R., Dalton, J., Wu, J., Pappo, A., and Bahrami, A. (2015). TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci. Rep., 5.","DOI":"10.1038\/srep11200"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/modpathol.2016.37","article-title":"The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing","volume":"29","author":"Wu","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/PAS.0000000000000611","article-title":"Primary and metastatic cutaneous melanomas express ALK through alternative transcriptional initiation","volume":"40","author":"Busam","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature15258","article-title":"Alternative transcription initiation leads to expression of a novel ALK isoform in cancer","volume":"526","author":"Wiesner","year":"2015","journal-title":"Nature"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cll.2017.05.003","article-title":"Toward a molecular-genetic classification of Spitzoid neoplasms","volume":"37","author":"Tetzlaff","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pathol.2015.12.007","article-title":"Genomic aberrations in spitzoid melanocytic tumors and their implications for diagnosis, prognosis and therapy","volume":"48","author":"Wiesner","year":"2016","journal-title":"Pathology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/labinvest.2016.122","article-title":"A review of kinase fusions in melanocytic tumors","volume":"97","author":"Shalin","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Yeh, I., de la Fouchardiere, A., Pissaloux, D., Mully, T.W., Garrido, M.C., Vemula, S.S., Busam, K.J., LeBoit, P.E., and McCalmont, T.H. Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. Am. J. Surg. Pathol., 39, 581\u2013591.","DOI":"10.1097\/PAS.0000000000000387"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.seminoncol.2016.08.003","article-title":"Genetic predisposition to melanoma","volume":"43","author":"Hewkes","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/bjd.14897","article-title":"Genetic susceptibility to cutaneous melanomas in southern Switzerland: Role of CDKN2A, MCIR and MTIF","volume":"175","author":"Mangas","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ng.3373","article-title":"Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma","volume":"47","author":"Law","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3927","article-title":"A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF","volume":"49","author":"Choi","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1195-328","article-title":"Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans","volume":"11","author":"Valverde","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1002\/humu.20788","article-title":"Red hair is the null phenotype of MC1R","volume":"29","author":"Beaumont","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0140-6736(00)02042-0","article-title":"Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair","volume":"355","author":"Healy","year":"2000","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/pcmr.12252","article-title":"Significance of the melanocortin 1 receptor in the DNA damage response of human melanocytes to ultraviolet radiation","volume":"27","author":"Swope","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/ng.411","article-title":"Genome-wide association study identifies three loci associated with melanoma risk","volume":"41","author":"Bishop","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Robles-Espinoza, C.D., Roberts, N.D., Chen, S., Leacy, F.P., Alexandrov, L.B., Pornputtapong, N., Halaban, R., Krauthammer, M., Cui, R., and Timothy Bishop, D. (2016). Germline MC1 status influences somatic mutations burden in melanoma. Nat. Commun., 7.","DOI":"10.1038\/ncomms12064"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature23887","article-title":"Palmitoylation-dependent activation of MC1R prevents melanomagenesis","volume":"549","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Tailor, N.T., Mitra, N., Goldstein, A.M., Tucker, M.A., Aviril, M.F., Azizi, E., Bergman, W., Bishop, D.T., Bressac-de-Pailleretes, S., and Bruno, W. (2017). Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families. J. Investig. Dermatol.","DOI":"10.1016\/j.jid.2017.07.829"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jaad.2017.05.050","article-title":"Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status","volume":"77","author":"Helgadottir","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Bonet, C., Luciani, F., Ottavi, J.F., Leclerc, J., Jouenne, F.M., Boncompagni, M., Bille, K., Hofman, V., Bossis, G., and Marco de Donatis, G. (2017). Deciphering the role of oncogenic MITFE318K in senescence delay and melanoma progression. J. Natl. Cancer Inst., 109.","DOI":"10.1093\/jnci\/djw340"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Berrookove","year":"2009","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ccell.2016.04.015","article-title":"ARF6 is an actionable node that orchestrates oncogenic GNAQ signaling in uveal melanoma","volume":"29","author":"Yoo","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Griewank","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predispose sto uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Pilarski","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1755-148X.2012.00979.x","article-title":"The genetics of uveal melanoma: An emerging framework for targeted therapy","volume":"25","author":"Harbour","year":"2012","journal-title":"Pigment Melanoma Cell Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","article-title":"Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing","volume":"99","author":"Torsello","year":"2016","journal-title":"Am. J. Hum. Gen."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0140-6736(96)90736-9","article-title":"Prognostic implications of monosomy 3 in uveal melanoma","volume":"347","author":"Prescher","year":"1996","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.2523","article-title":"Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma","volume":"45","author":"Harbour","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Alsafadi, S., Houy, A., Battistella, A., Popova, T., Wassef, M., Henry, E., Tirode, F., Constantinou, A., Piperno-Neumann, S., and Roman-Roman, S. (2016). Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun., 7.","DOI":"10.1038\/ncomms10615"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: A distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzygitoglu","year":"2016","journal-title":"Ophtalmology"},{"key":"ref_140","first-page":"435","article-title":"S3BF1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms","volume":"127","author":"Creytens","year":"2016","journal-title":"Arch. Neuropathol. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ng.3549","article-title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma","volume":"48","author":"Moore","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.18632\/oncotarget.6614","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2015","journal-title":"Oncotarget"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","article-title":"Driver mutations in uveal melanoma: Associations with gene expression profile and patient outcomes","volume":"134","author":"Decatur","year":"2016","journal-title":"JAMA Ophtalmol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin. Cancer. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1101\/gad.296962.117","article-title":"Focus on cutaneous and uveal melanoma specificities","volume":"31","author":"Pandiani","year":"2017","journal-title":"Genes Dev."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"40683","DOI":"10.18632\/oncotarget.16542","article-title":"Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations","volume":"8","author":"Cosgarea","year":"2017","journal-title":"Oncotarget"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbour BRAF and NRAS mutations and copy number changes similar to cutaneous melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CMR.0000000000000345","article-title":"Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and mutations of NF1 and KIT in mucosal melanoma","volume":"27","author":"Hintzsche","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.2013.312","article-title":"TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumors","volume":"109","author":"Griewank","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 2253 cases of nongynecological melanoma","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ng.3382","article-title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway","volume":"47","author":"Shain","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"9011\u20139011","DOI":"10.1200\/jco.2015.33.15_suppl.9011","article-title":"Response to anti-PD1\/PDL1 therapy in patients with metastatic desmoplastic melanoma","volume":"33","author":"Eroglu","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/modpathol.2016.210","article-title":"Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and mixed cytomorphological variant","volume":"30","author":"Frydenlund","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.humpath.2016.02.012","article-title":"Neurofibromin protein loss in desmoplastic melanoma subtypes: Implicating NF1 allelic loss as a distinct genetic driver?","volume":"53","author":"Kadokoura","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CMR.0000000000000272","article-title":"Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: Analyses of 76 cases","volume":"26","author":"Yang","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 gene in tumor syndromes and melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jid.2016.05.095","article-title":"Rasopathy gene mutations in melanoma","volume":"136","author":"Halaban","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/DAD.0b013e31827a0b98","article-title":"SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics","volume":"35","author":"Palla","year":"2013","journal-title":"Am. J. Dermopathol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"530","DOI":"10.5858\/arpa.2014-0077-OA","article-title":"A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas","volume":"139","author":"Tacha","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.jid.2016.07.015","article-title":"5-hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma","volume":"136","author":"Pavlova","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"315","DOI":"10.18632\/oncotarget.13324","article-title":"Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma","volume":"8","author":"Gong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13148-017-0332-8","article-title":"Aberrant DNA methylation in melanoma: Biomarker and therapeutic opportunities","volume":"9","author":"Micevic","year":"2017","journal-title":"Clin. Epigenetics"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/jid.2015.61","article-title":"Genome-wide DNA methylation analysis in melanoma reveals the importance of CpG methylation in MITF regulation","volume":"135","author":"Lauss","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Wouters, J., Vizoso, M., Martinez-Cardus, A., Carmona, F.J., Govaere, O., Laguna, T., Joseph, J., Dynoodt, P., Aura, C., and Foth, M. (2017). Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma. BMC Med., 15.","DOI":"10.1186\/s12916-017-0851-3"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.celrep.2017.03.078","article-title":"Systemic epigenomic analysis reveals chromatic states associated with melanoma progression","volume":"19","author":"Fiziev","year":"2017","journal-title":"Cell Rep."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Badal, B., Solovyov, A., Di Cecilia, S., Chan, J.M., Chang, L.W., Iqbal, R., Aydin, I., Rayan, G., Chen, C., and Abbate, F. (2017). Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. JCI Insight, 2.","DOI":"10.1172\/jci.insight.92102"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome","volume":"16","author":"Jonsson","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1158\/1078-0432.CCR-12-0343","article-title":"Molecular profiling reveals low- and high-grade forms of primary melanoma","volume":"18","author":"Harbst","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"11683","DOI":"10.18632\/oncotarget.3549","article-title":"Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort","volume":"6","author":"Nsengimana","year":"2015","journal-title":"Oncotarget"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"12297","DOI":"10.18632\/oncotarget.3655","article-title":"Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy","volume":"6","author":"Cirenajwis","year":"2015","journal-title":"Oncotarget"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.jid.2016.05.119","article-title":"Consensus of melanoma gene expression subtypes converges on biological entities","volume":"136","author":"Lauss","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"14415","DOI":"10.18632\/oncotarget.7361","article-title":"Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma","volume":"7","author":"Lardone","year":"2016","journal-title":"Oncotarget"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-17-0172","article-title":"Gene expression profiling in BRAF-mutated melanoma patients reveals patient subgroups with poor outcomes to Vemurafenib that may be overcome by Cobimetinib plus Vemurafenib","volume":"23","author":"Wongchenko","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Lauss, M., Ringner, M., Karlsson, A., Harbst, K., Busch, C., Geisler, J., Lonning, P.E., Staaf, J., and Jonsson, G. (2015). DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Med. Genom., 8.","DOI":"10.1186\/s12920-015-0147-4"},{"key":"ref_177","unstructured":"Morab, B., Silva, R., Perry, A.S., and Gallagher, W.M. (2017). Epigenetics of malignant melanoma. Semin. Cancer Biol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/CMR.0b013e32833b7c7c","article-title":"Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns","volume":"20","author":"Harbst","year":"2010","journal-title":"Melanoma Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/path.4318","article-title":"Molecular and genetic diversity in the metastatic process of melanoma","volume":"233","author":"Harbst","year":"2014","journal-title":"J. Pathol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1073\/pnas.1508074112","article-title":"Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination","volume":"112","author":"Sanborn","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1158\/0008-5472.CAN-15-3476","article-title":"Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma","volume":"76","author":"Harbst","year":"2016","journal-title":"Cancer Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drug in melanoma","volume":"5","author":"Muller","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Ennen, M., Keime, C., Gambi, G., Kieny, A., Coassolo, S., Thibault-Carpentier, C., Margerin-Schaller, F., Davidson, G., Vagne, C., and Lipsker, D. (2017). MITF-high and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra and inter-tumoral heterogeneity of primary melanoma. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-17-0010"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Li, J., Yan, S., Liu, Z., Zhou, Y., Pan, Y., Yuan, W., Liu, M., Tan, Q., Tian, G., and Dong, B. (2017). Multiregional sequencing reveals genomic alterations and clonal dynamics in primary malignant melanoma of the esophagus. Cancer Res.","DOI":"10.1158\/0008-5472.CAN-17-0938"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/cncr.30684","article-title":"Genetically engineered mouse models of melanoma","volume":"123","author":"Day","year":"2017","journal-title":"Cancer"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/labinvest.2016.155","article-title":"Mouse models of UV-induced melanoma: Genetics, pathology, and clinical relevance","volume":"17","author":"Day","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.0022-202X.2005.23917.x","article-title":"Neonatal ultraviolet radiation exposure is critical for malignant melanoma induction in pigmented Tpras transgenic mice","volume":"125","author":"Hacker","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/0008-5472.CAN-04-2970","article-title":"Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background","volume":"65","author":"Ackermann","year":"2005","journal-title":"Cancer Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ccr.2009.02.022","article-title":"Oncogenic Braf induces melanocyte senescence and melanoma in mice","volume":"15","author":"Dhomen","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/onc.2009.95","article-title":"Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice","volume":"28","author":"Goel","year":"2009","journal-title":"Oncogene"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"BRAFV600E cooperates with Pten loss to induce metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Kaufman, C.K., Mosimann, C., Fan, Z.P., Yang, S., Thomas, A.J., Ablain, J., Tan, J.L., Fogley, R.D., van Rooijen, E., and Hagedorn, E.J. (2016). A zebrafish melanoma model reveals emergence of neural crest identity during melanomas initiation. Science, 351.","DOI":"10.1126\/science.aad2197"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1242\/dev.106567","article-title":"The melanocyte lineage in development and disease","volume":"142","author":"Mort","year":"2015","journal-title":"Development"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/pcmr.12375","article-title":"Maintenance of distict melanocyte populations in the interfollicular epidermis","volume":"28","author":"Glover","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.stem.2017.08.003","article-title":"Mouse cutaneous melanoma induced by mutant BRaf arises from expansion and dedifferentiation of mature pigmented melanocytes","volume":"21","author":"Kohler","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.stem.2017.09.001","article-title":"Melanocyte stem cell activation and translocation initiate cutaneous melanoma in response to UV exposure","volume":"21","author":"Moon","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-319-56017-5_7","article-title":"Ultraviolet radiations: Skin defense-damage mechanism","volume":"996","author":"Mohania","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17460441.2016.1216968","article-title":"Patient-derived tumor xenograft models for melanoma drug discovery","volume":"11","author":"Harris","year":"2016","journal-title":"Exp. Opin. Drug. Discov."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.18632\/oncotarget.2445","article-title":"Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions","volume":"5","author":"Einarsdottir","year":"2014","journal-title":"Oncotarget"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Salangsang","year":"2013","journal-title":"Nature"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor need broad target blockade in BRAF-mutated melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","article-title":"A tumorigenic subpopulation with stem cell properties in melanomas","volume":"65","author":"Fang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1073\/pnas.1009069108","article-title":"Eradication of melanomas by targeted elimination of a minor subset of tumor cells","volume":"108","author":"Schmidt","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"313","DOI":"10.18632\/oncotarget.259","article-title":"The beating heart of melanomas: A great minor subset of cancer cells sustains tumor growth","volume":"2","author":"Schmidt","year":"2011","journal-title":"Oncoterget"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2012.27","article-title":"Targeting CD20 in melanoma patients at high risk of disease recurrence","volume":"20","author":"Pinc","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.437","article-title":"Regression of metastatic melanoma by targeting cancer stem cells","volume":"3","author":"Schlaak","year":"2012","journal-title":"Oncotarget"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1166\/jbn.2015.2129","article-title":"CD20 antibody-conjugated immunoliposomes for targeted chemotherapy of melanoma cancer initiating cells","volume":"11","author":"Song","year":"2015","journal-title":"J. Biomed. Nanothechnol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41467-017-00452-4","article-title":"Tumor-associated B-cells induce tumor heterogeneity and therapy resistance","volume":"8","author":"Somasundaram","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ejca.2007.01.017","article-title":"Melanoma contains CD133 and ABCG2 positive cells with enhanced tumorigenic potential","volume":"43","author":"Monzani","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/modpathol.3800720","article-title":"Increased expression of stem cell markers in malignant melanoma","volume":"20","author":"Klein","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1634\/stemcells.2008-0601","article-title":"The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma","volume":"26","author":"Rappa","year":"2008","journal-title":"Stem Cells"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","article-title":"Identification of cells initiating melanomas","volume":"451","author":"Schatton","year":"2008","journal-title":"Nature"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/jid.2009.296","article-title":"Induction of terminal differentiation in melanoma cells on downregulation of beta-amyloid precursor protein","volume":"130","author":"Botelho","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2008.02.022","article-title":"MDR1 expression identifies human melanoma stem cells","volume":"368","author":"Keshet","year":"2008","journal-title":"Biochim. Biophys. Res. Commun."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Chartrain, M., Riond, J., Stennevin, A., Vandenberghe, I., Gomes, B., Lamant, L., Meyer, N., Gairin, J.E., Guilbaud, N., and Annereau, J.P. (2012). Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036762"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1158\/0008-5472.CAN-04-3327","article-title":"ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma","volume":"65","author":"Frank","year":"2005","journal-title":"Cancer Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1158\/0008-5472.CAN-12-0624","article-title":"CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenesis through vasculogenic mimicry","volume":"72","author":"Lai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/0008-5472.CAN-10-1660","article-title":"VEGF-R1 expressed by malignant melanoma-initiating cells is required for tumor growth","volume":"71","author":"Frank","year":"2011","journal-title":"Cancer Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/jid.2010.377","article-title":"RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells","volume":"131","author":"Kupas","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/stem.1333","article-title":"The PI3K\/AKT signaling pathway controls the quiescence of the low-rhodamine 123-retention cells compartment essential for melanoma stem cells","volume":"31","author":"Touil","year":"2013","journal-title":"Stem Cells"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/modpathol.2012.71","article-title":"Profiling of ABC transporters ABCB5, ABCF2 and enstin-positive stem cells in nevi, in situ and invasive melanoma","volume":"25","author":"Setia","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbrc.2013.06.006","article-title":"Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk","volume":"436","author":"Lin","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/0008-5472.CAN-14-0582","article-title":"ABCB5 maintains melanoma-initiating cells through a pro-inflammatory cytokine signaling circuit","volume":"74","author":"Wilson","year":"2014","journal-title":"Cancer Res."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bbrc.2017.08.052","article-title":"ABCB5 promotes melanoma metastasis through enhancing NF-kB p65 protein stability","volume":"492","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature07567","article-title":"Efficient tumor formation by single human melanoma cells","volume":"456","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1755-148X.2010.00690.x","article-title":"Human malignat melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells","volume":"23","author":"Prasmickaite","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2009.10.021","article-title":"Cancer stem cells sustaining the growth of mouse melanoma are not rare","volume":"292","author":"Zhong","year":"2010","journal-title":"Cancer Lett."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature09161","article-title":"Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271","volume":"466","author":"Boiko","year":"2010","journal-title":"Nature"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1158\/0008-5472.CAN-10-3997","article-title":"Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth","volume":"71","author":"Civenni","year":"2011","journal-title":"Cancer Res."},{"key":"ref_233","first-page":"588","article-title":"Stem cell marker CD271 is expressed by vascular mimicry-priming uveal melanoma cells in three-dimensional cultures","volume":"18","author":"Kormos","year":"2012","journal-title":"Mol. Vis."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1038\/onc.2011.656","article-title":"Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation","volume":"31","author":"Kumar","year":"2012","journal-title":"Oncogene"},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Redmer, T., Welte, Y., Behrens, D., Fichtner, I., Przybilla, D., Wruck, W., Yaspo, M.L., Lehrach, H., Sch\u00e4fer, R., and Regenbrecht, C.R. (2014). The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092596"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-15-2377","article-title":"CD271 expression on patient melanoma cells is unstable and unlinked to tumorigenicity","volume":"76","author":"Bayle","year":"2016","journal-title":"Cancer Res."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2016.07.004","article-title":"Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts","volume":"16","author":"Ngo","year":"2016","journal-title":"Cell Rep."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/onc.2010.598","article-title":"Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny","volume":"30","author":"Cheli","year":"2011","journal-title":"Oncogene"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.18632\/oncotarget.1967","article-title":"CD271 is an imperfect marker for melanoma initiating cells","volume":"5","author":"Cheli","year":"2014","journal-title":"Oncotarget"},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Radke, J., Robner, F., and Redmer, T. (2017). CD271 determines migratory properties of melanoma cells. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-10129-z"},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Redmer, T., Walz, I., Kliunger, B., Khouja, S., Welte, Y., Schafer, R., and Regenbrecht, C. (2017). The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis, 6.","DOI":"10.1038\/oncsis.2016.88"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","article-title":"A temporally distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth","volume":"141","author":"Roesch","year":"2010","journal-title":"Cell"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.10.012","article-title":"Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and nor hierarchically organized","volume":"18","author":"Quintana","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Prasmiekhaite, L., Engesaeter, B.O., Skrbo, N., Hellenes, T., Kristian, A., Oliver, N.K., Suo, Z., and M\u00e6landsmo, G.M. (2010). Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0010731"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/jcb.23406","article-title":"Expression and activity of alcohol and aldehyde dehydrogenases in melanoma cells and in melanocytes","volume":"113","author":"Amann","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/jid.2010.237","article-title":"Selection of melanoma tumorigenic cells using ALDH","volume":"130","author":"Boonyaratanakornkit","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/stem.1160","article-title":"HEDGEHOG-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells","volume":"30","author":"Santini","year":"2012","journal-title":"Stem Cells"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/stem.1193","article-title":"ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets","volume":"30","author":"Luo","year":"2012","journal-title":"Stem Cells"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1038\/onc.2017.160","article-title":"ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment","volume":"36","author":"McGrail","year":"2017","journal-title":"Oncogene"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Taghizadeh, R., Noh, M., HuH, Y., Ciusani, E., Sigalotti, L., Maio, M., Arosio, B., Nicotra, M.R., Natali, P., and Sherley, J.L. (2010). CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015183"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1038\/onc.2010.350","article-title":"Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population","volume":"29","author":"Kalabis","year":"2010","journal-title":"Oncogene"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ncb2535","article-title":"Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma","volume":"14","author":"Shakhova","year":"2012","journal-title":"Nat. Cell. Biol."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Shakhova, O., Cheng, P., Mishra, P.J., Zingg, D., Schaefer, S.M., Debbache, J., Hausel, J., Matter, C., Guo, T., and Davis, S. (2015). Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. PLoS Genet., 11.","DOI":"10.1371\/journal.pgen.1004877"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ccr.2014.04.030","article-title":"RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway","volume":"26","author":"Cifdaloz","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1038\/onc.2014.71","article-title":"SOX2 regulates self-renewal and tumorigenesis of human melanoma-initiating cells","volume":"33","author":"Santini","year":"2014","journal-title":"Oncogene"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/0008-5472.CAN-07-2491","article-title":"In vivo switching of human melanoma cells between proliferative and invasive states","volume":"68","author":"Hoek","year":"2008","journal-title":"Cancer Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1158\/0008-5472.CAN-08-1053","article-title":"Brn-2 represses microphtalmia-associated transcription factor expression and marks a distinct subpopulation of microphtalmia-associated transcription factor-negative melanoma cells","volume":"68","author":"Goodall","year":"2008","journal-title":"Cancer Res"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1038\/onc.2011.33","article-title":"Inversion expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumor xenografts regulate NOTCH pathway","volume":"30","author":"Thurber","year":"2011","journal-title":"Oncogene"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"7969","DOI":"10.1158\/0008-5472.CAN-09-0781","article-title":"Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination","volume":"69","author":"Pinner","year":"2009","journal-title":"Cancer Res."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","article-title":"Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A","volume":"19","author":"Arozarena","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1535-7163.MCT-16-0535","article-title":"The slow cycling phenotype: A growing problem for treatment resistance in melanoma","volume":"16","author":"Ahn","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Perego, M., Maurer, M., Wang, J.K., Shaffer, S., Muller, A.C., Parapatics, K., Li, L., Hristova, D., Shin, S., and Keeney, F. (2017). A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene.","DOI":"10.1038\/onc.2017.341"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature20791","article-title":"Targeting metastasis-initiating cells through the fatty acid receptor CD36","volume":"541","author":"Pascual","year":"2017","journal-title":"Nature"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1128\/MCB.01067-12","article-title":"A PI3K-Pax3 axis regulates BRN-2 expression in melanoma","volume":"32","author":"Bonvin","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/onc.2011.425","article-title":"Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells","volume":"31","author":"Cheli","year":"2012","journal-title":"Oncogene"},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Romano, S., Staibano, S., Greco, A., Brunetti, A., Nappo, G., Ilardi, G., Martinelli, R., Sorrentino, A., Di Pace, A., and Mascolo, M. (2013). FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential. Cell Death Dis., 4.","DOI":"10.1038\/cddis.2013.109"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.4161\/cc.24601","article-title":"The significance of a Cripto-1-positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics","volume":"12","author":"Strizzi","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Quintana, E., Piskounova, E., Shackleton, M., Weinberg, D., Eskiocak, U., Fullen, D.R., Johnson, T.M., and Morrison, S.J. (2012). Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci. Transl. Med., 4.","DOI":"10.1126\/scitranslmed.3004599"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/0008-5472.CAN-09-2153","article-title":"Characterization of melanoma cells capable of propagating tumors from a single cell","volume":"70","author":"Held","year":"2010","journal-title":"Cancer Res."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/jid.2011.159","article-title":"From cancer stem cells to tumor maintenance in melanoma","volume":"131","author":"Roesch","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible differentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1158\/1078-0432.CCR-13-0061","article-title":"Effective activity of cytokine-induced killer cells against autologous metastatic melanoma, including cells with stemness features","volume":"19","author":"Gammaitoni","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Ostyn, P., El Machhour, R., Bagard, S., Kotecki, N., Vandomme, J., Flamenco, P., Segard, P., Masselot, B., Formstecher, P., and Touil, Y. (2014). Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma. Cell Commun. Signal., 12.","DOI":"10.1186\/s12964-014-0052-z"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrc3820","article-title":"Challenges in circulating tumour cell research","volume":"14","author":"Pantel","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.celrep.2014.03.039","article-title":"Isolation and molecular characterization of circulating melanoma cells","volume":"7","author":"Luo","year":"2014","journal-title":"Cell Rep."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nmeth.3404","article-title":"A microfluidic device for label-free, physical capture of circulating tumor cell clusters","volume":"12","author":"Sarioglu","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Ozkumur, E., Shah, A.M., Ciciliano, J.C., Emmink, B.L., Miyamoto, D.T., Brachel, E., Yu, M., Chen, P.I., Morgan, B., and Trautwein, J. (2013). Inertial focusing for tumor-antigen-dependent and-independent sorting of rare circulating tumor cells. Sci. Transl. Med., 5.","DOI":"10.1126\/scitranslmed.3005616"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"67355","DOI":"10.18632\/oncotarget.18641","article-title":"Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device","volume":"8","author":"Marvasela","year":"2017","journal-title":"Oncotarget"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","article-title":"Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma","volume":"6","author":"Girotti","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1541-7786.MCR-16-0431","article-title":"Next-generation sequencing analysis and algorithmas for PDX and CDX models","volume":"15","author":"Kandhelwal","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","article-title":"Circulating tumor DNA (ctDNA) as a liquid biopsy for melanoma","volume":"404","author":"Calapre","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials","volume":"22","author":"Gagnon","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Gangadhar, T.C., Savitch, S.L., Yee, S.S., Xu, W., Huang, A.C., Harmon, S., Lieberman, D.B., Soucier, D., Fan, R., and Black, T.A. (2017). Feasibility of monitoring advancer melanoma patients using cell-free DNA from plasma. Cancer Res.","DOI":"10.1111\/pcmr.12623"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/annonc\/mdw278","article-title":"Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA","volume":"27","author":"Gremel","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapiues: Optimizinbg outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T cell invigoration to tumor burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): Secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2017.06.021","article-title":"Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis","volume":"83","author":"Zhang","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"Weber, J., Mandala, M., Del Vecchio, M., Gogas, H.J., Arance, A.M., Cowey, C.L., Dalle, S., Schenker, M., Chiarion-Sileni, V., and Marquez-Rodas, I. (2017). Adjuvant nivolumab bersus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1709030"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_297","doi-asserted-by":"crossref","unstructured":"Lin, Z., Chen, X., Li, Z., Luo, Y., Fang, Z., Xu, B., and Han, M. (2016). PD-1 antibody monotherapy for malignant melanoma: A systematic review and meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160485"},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Larkin, J., Minor, D., D\u2019Angelo, S., Neyns, B., Smylie, M., Miller, W.H., Gutzmer, R., Lenette, G., Chmielowski, B., and Lao, C.D. (2017). Overall survival in aptients with advanced melanoma who received Nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial. J. Clin. Oncol.","DOI":"10.1200\/JCO.2016.71.8023"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_300","unstructured":"Postow, M., Chesney, J., Pavlick, A., Robert, C., Grossmann, K., McDermott, D., Linette, G., Meyer, N., Giguere, J., and Agarwala, S. (2016, January 16\u201320). Initial report of overall survival rates from a randomized phase II trial evaluating the combination of Nivolumab (NIVO) and Ipilimumab (IPI) in patients with advanced melanoma (MEL) [abstract]. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA, USA."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_303","doi-asserted-by":"crossref","unstructured":"Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, L., Lao, C., Schadendorf, D., Ferrucci, P.F., and Smyle, M. (2016). Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-na\u00efve patients (pts) with advanced melanoma (MEL) (CheckMate 067). J. Clin. Oncol., 34.","DOI":"10.1200\/JCO.2016.34.15_suppl.9505"},{"key":"ref_304","doi-asserted-by":"crossref","unstructured":"Goldstein, D.A. (2017). Adjuvant ipilimumab for melanoma-The $1.8 million per patient regimen. JAMA Oncol.","DOI":"10.1001\/jamaoncol.2017.3123"},{"key":"ref_305","doi-asserted-by":"crossref","unstructured":"Schadendorf, D., Wolchok, J.D., Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., and Chesney, J. (2017). Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials. J. Clin. Oncol.","DOI":"10.1200\/JCO.2017.73.2289"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CLTA-4 blockade in metastatic melanoma","volume":"350","author":"Miao","year":"2015","journal-title":"Science"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J. Immunol."},{"key":"ref_314","doi-asserted-by":"crossref","unstructured":"Koyama, S., Akbay, E.A., Li, Y.Y., Herter-Sprie, G.S., Buczkowski, K.A., Richards, W.G., Gandhi, L., Redig, A.J., Rodig, S.J., and Asahina, H. (2016). Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun., 7.","DOI":"10.1038\/ncomms10501"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumor immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yelds insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_319","doi-asserted-by":"crossref","unstructured":"Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., and Weide, B. (2017). Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat. Commun., 8.","DOI":"10.1038\/ncomms15440"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neontigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2017","journal-title":"Science"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"167","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","article-title":"Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immnol. Res."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"e21035\u2013e21035","DOI":"10.1200\/JCO.2017.35.15_suppl.e21035","article-title":"NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts","volume":"35","author":"Kirchberger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenibin davanced BRAFV600-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_330","doi-asserted-by":"crossref","unstructured":"Long, G.V., Hauschild, A., Santinami, M., Atkinson, V., Mandal\u00e0, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., and Haydon, A. (2017). Ajuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1708539"},{"key":"ref_331","doi-asserted-by":"crossref","unstructured":"Long, G.V., Eraglu, Z., Infante, T., Patel, S., Dand, A., Johnson, D.B., Gonzalez, R., Kefford, R., Hamid, O., and Schuchter, L. (2017). Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafebib combined with trametinib. J. Clin. Oncol.","DOI":"10.1200\/JCO.2017.74.1025"},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMB-MB): A multicenter, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","article-title":"Combination of Dabrafenib plus Trametinib for BRAF and MEK inhibitor treated patients with advanced BRAF V600-mutant melanoma: An open \u00f2label, single arm, dual-centre, phase 2 clinical trial","volume":"18","author":"Schreuer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature24037","article-title":"Cancer drug addiction is relayed by an ERK2-dependent phenotype switch","volume":"550","author":"Kong","year":"2017","journal-title":"Nature"},{"key":"ref_335","unstructured":"Hong, A., Moriceau, G., Sun, L., Lomely, S., Piva, M., Daimoseaux, R., Holmen, S.L., Sharpless, N.E., Hugo, W., and Lo, R.S. (2017). Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma. Cancer Discov."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.02.003","article-title":"Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy","volume":"29","author":"Smith","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_337","first-page":"1011","article-title":"Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure","volume":"9","author":"Smith","year":"2017","journal-title":"EMBO J."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2159-8290.CD-16-0955","article-title":"Biomarker accessible and chemically addressable mechanistic subtypes of BRAF melanoma","volume":"7","author":"Esciocak","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature15726","article-title":"Oxidative stress inhibits distant metastasis by human melanoma cells","volume":"527","author":"Piskounova","year":"2015","journal-title":"Nature"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/5\/4\/28\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:50:25Z","timestamp":1760208625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/5\/4\/28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":339,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["medsci5040028"],"URL":"https:\/\/doi.org\/10.3390\/medsci5040028","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]}}}